Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 69

1.

The Serotonin 5-HT1A Receptor Agonist Tandospirone Improves Executive Function in Common Marmosets.

Baba S, Murai T, Nakako T, Enomoto T, Ono M, Shimizu I, Ikeda K.

Behav Brain Res. 2015 Mar 21. pii: S0166-4328(15)00190-4. doi: 10.1016/j.bbr.2015.03.025. [Epub ahead of print]

PMID:
25804359
2.

Addressing the Right Targets in Oncology: Challenges and Alternative Approaches.

Stock JK, Jones NP, Hammonds T, Roffey J, Dillon C.

J Biomol Screen. 2015 Mar;20(3):305-317. Epub 2015 Jan 22. Review.

PMID:
25614505
3.

Procognitive effect of AC-3933 in aged mice, and synergistic effect of combination with donepezil in scopolamine-treated mice.

Hashimoto T, Hatayama Y, Nakamichi K, Yoshida N.

Eur J Pharmacol. 2014 Dec 15;745:123-8. doi: 10.1016/j.ejphar.2014.10.015. Epub 2014 Oct 18.

PMID:
25446931
4.
5.

Structural basis for translocation by AddAB helicase-nuclease and its arrest at χ sites.

Krajewski WW, Fu X, Wilkinson M, Cronin NB, Dillingham MS, Wigley DB.

Nature. 2014 Apr 17;508(7496):416-9. doi: 10.1038/nature13037. Epub 2014 Mar 16.

6.

Translational research into species differences of endocrine toxicity via steroidogenesis inhibition by SMP-028--for human safety in clinical study.

Nishizato Y, Imai S, Okahashi N, Yabunaka A, Kunimatsu T, Kikuchi K, Yabuki M.

Toxicol Appl Pharmacol. 2014 May 1;276(3):213-9. doi: 10.1016/j.taap.2014.02.016. Epub 2014 Mar 1.

PMID:
24593921
7.

Selective AKR1C3 inhibitors do not recapitulate the anti-leukaemic activities of the pan-AKR1C inhibitor medroxyprogesterone acetate.

Khanim F, Davies N, Veliça P, Hayden R, Ride J, Pararasa C, Chong MG, Gunther U, Veerapen N, Winn P, Farmer R, Trivier E, Rigoreau L, Drayson M, Bunce C.

Br J Cancer. 2014 Mar 18;110(6):1506-16. doi: 10.1038/bjc.2014.83. Epub 2014 Feb 25.

8.

Pharmacological properties of AC-3933, a novel benzodiazepine receptor partial inverse agonist.

Hashimoto T, Kiyoshi T, Kohayakawa H, Iwamura Y, Yoshida N.

Neuroscience. 2013 Oct 24. pii: S0306-4522(13)00884-1. doi: 10.1016/j.neuroscience.2013.10.031. [Epub ahead of print]

PMID:
24513525
9.

In vivo pharmacological characterization of AC-3933, a benzodiazepine receptor partial inverse agonist for the treatment of Alzheimer's disease.

Hatayama Y, Hashimoto T, Kohayakawa H, Kiyoshi T, Nakamichi K, Kinoshita T, Yoshida N.

Neuroscience. 2014 Apr 18;265:217-25. doi: 10.1016/j.neuroscience.2014.01.063. Epub 2014 Feb 8.

PMID:
24513386
10.

Lack of dopamine D4 receptor affinity contributes to the procognitive effect of lurasidone.

Murai T, Nakako T, Ikeda K, Ikejiri M, Ishiyama T, Taiji M.

Behav Brain Res. 2014 Mar 15;261:26-30. doi: 10.1016/j.bbr.2013.11.036. Epub 2013 Dec 1.

PMID:
24304719
11.

Synthesis and pharmacological characterization of 1-benzyl-4-aminoindole-based thyroid hormone receptor β agonists.

Takahashi N, Maeda K, Asano Y, Watanabe N.

Bioorg Med Chem. 2014 Jan 1;22(1):488-98. doi: 10.1016/j.bmc.2013.11.001. Epub 2013 Nov 13.

PMID:
24290064
12.

Modulation of inflammatory pain in response to a CCR2/CCR5 antagonist in rodent model.

Okamoto M, Suzuki T, Watanabe N.

J Pharmacol Pharmacother. 2013 Jul;4(3):208-10. doi: 10.4103/0976-500X.114605. No abstract available.

13.

Studying protein-ligand interactions using X-ray crystallography.

Turnbull AP, Emsley P.

Methods Mol Biol. 2013;1008:457-77. doi: 10.1007/978-1-62703-398-5_17.

PMID:
23729263
14.

A pharmacoeconomic analysis of in-hospital costs resulting from reintubation in preterm infants treated with lucinactant, beractant, or poractant alfa.

Guardia CG, Moya FR, Sinha S, Simmons PD, Segal R, Greenspan JS.

J Pediatr Pharmacol Ther. 2012 Jul;17(3):220-7. doi: 10.5863/1551-6776-17.3.220.

15.

Synthesis and pharmacological profile of a new selective G protein-coupled receptor 119 agonist; 6-((2-fluoro-3-(1-(3-isopropyl-1,2,4-oxadiazol-5-yl)piperidin-4-yl)propyl)amino)-2,3-dihydro-1H-inden-1-one.

Sakairi M, Kogami M, Torii M, Makino M, Kataoka D, Okamoto R, Miyazawa T, Inoue M, Takahashi N, Harada S, Watanabe N.

Chem Pharm Bull (Tokyo). 2012;60(9):1093-5.

16.

Synthesis and biological evaluation of a 6-aminofuro[3,2-c]pyridin-3(2H)-one series of GPR 119 agonists.

Sakairi M, Kogami M, Torii M, Kuno Y, Ohsawa Y, Makino M, Kataoka D, Okamoto R, Miyazawa T, Inoue M, Takahashi N, Harada S, Watanabe N.

Arzneimittelforschung. 2012 Nov;62(11):537-44. doi: 10.1055/s-0032-1323760. Epub 2012 Sep 12.

PMID:
22972470
17.

Synthesis and SAR studies of bicyclic amine series GPR119 agonists.

Sakairi M, Kogami M, Torii M, Kataoka H, Fujieda H, Makino M, Kataoka D, Okamoto R, Miyazawa T, Okabe M, Inoue M, Takahashi N, Harada S, Watanabe N.

Bioorg Med Chem Lett. 2012 Aug 1;22(15):5123-8. doi: 10.1016/j.bmcl.2012.05.117. Epub 2012 Jun 17.

PMID:
22765901
18.

Biological and functional characteristics of a novel low-molecular weight antagonist of glucose-dependent insulinotropic polypeptide receptor, SKL-14959, in vitro and in vivo.

Nakamura T, Tanimoto H, Mizuno Y, Tsubamoto Y, Noda H.

Diabetes Obes Metab. 2012 Jun;14(6):511-7. doi: 10.1111/j.1463-1326.2011.01555.x. Epub 2012 Jan 18.

PMID:
22192426
19.

Co-crystal structures of inhibitors with MRCKβ, a key regulator of tumor cell invasion.

Heikkila T, Wheatley E, Crighton D, Schroder E, Boakes A, Kaye SJ, Mezna M, Pang L, Rushbrooke M, Turnbull A, Olson MF.

PLoS One. 2011;6(9):e24825. doi: 10.1371/journal.pone.0024825. Epub 2011 Sep 20.

20.

Targeting cancer using fragment based drug discovery.

Turnbull AP, Boyd SM.

Anticancer Agents Med Chem. 2012 Jan;12(1):40-8.

PMID:
21707503
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk